Diko Kazandjian
@dikokaz
Followers
426
Following
942
Media
46
Statuses
712
Professor of Medicine, Myeloma Program @SylvesterCancer @univmiami
Miami
Joined April 2011
Important data from @NIHClinicalCntr highlighting why WB DW-MRI is a must prior to securing a diagnosis of Smoldering Myeloma [regardless of CT/PET-CT]: 📊Only 16% had pre-referral MRI 📊10% reclassified from SMM ➡️active MM based on MRI alone! https://t.co/iW22nF4uiR Also,
0
2
6
While single-arm, the 100% MRD-negativity at 10^-6 with short course of Linvosiltemab post-induction is striking! Awaiting the FASTER RCT [Elra vs ASCT] from @CoMMitTrials but hard to imagine Mel-200 will achieve such high MRD-conversion rate based on prior data! #ASH25
3) Abstract 248 (@dikokaz): Could consolidation with a bispecific antibody supplant transplant? IMMUNOPLANT is a ph2 study enrolling patients with MRD positivity after 4+ cycles of induction. 💉Patients received 4-6 cycles of linvoseltamab before maintenance 👍MRD conversion to
0
1
16
Topline results for ADVANCE: Dara-KRd vs KRd MRD <10^-5 higher with Dara-KRd - The scale for PFS is adjusted here to accentuate differences, but we don't see a difference...at least not yet. - Don't know how many patients went to ASCT in either arm (more in KRd arm?) -
7503 – ADVANCE Trial: MRD-adapted Dara-KRd vs KRd in NDMM DKRd significantly boosted MRD-negativity (59% vs 36%, p<0.001). Transplant was optional for MRD+. At 32.7 months, PFS was 86% DKRd vs 79% KRd. 🧠 My take: MRD as primary endpoint is welcome. How many MRD-pos went to
1
7
33
ICYMI: In newly diagnosed multiple myeloma (NDMM), the addition of daratumumab (D) to the KRd regimen significantly improved minimal residual disease (MRD) negativity. In the ADVANCE clinical trial (NCT04268498), 306 patients received either DKRd or KRd for 8 cycles. Results
1
10
38
And that's a wrap on #MyelomaMRD2025! We just heard from @BenDiamondMD, David Coffey & Hans Lee (@MDAndersonNews), who highlighted exciting new MRD technologies emerging in myeloma! @SylvesterCancer #mmMRD #MMsm
0
2
7
One week left. Thank you for supporting Sylvester and our myeloma institute
https://t.co/bq1jMEJ0gx Consider supporting me and Team Myeloma for the DCC fundraising cancer challenge.
0
0
2
https://t.co/bq1jMEJ0gx Consider supporting me and Team Myeloma for the DCC fundraising cancer challenge.
0
0
0
BREAKING: RFK, Jr. condemns Azerbaijan's ethnic-cleansing of #Artsakh, pledges to use his power as president of the USA to peacefully reunite #Armenia. Location: @RobertKennedyJr speech Burbank, CA event (1/8/24) hosted by community benefactor Mike Sarian Video: @AlphaNewsAM
7
22
156
This is @RobertKennedyJr - under consideration today for a cabinet level post - demanding justice for the Armenian nation, the return of Armenians to Artsakh.
25
124
582
1
1
11
Clearing the path for MRD as early endpoint in multiple myeloma. Conversation with @DrOlaLandgren of @SylvesterCancer. https://t.co/mKlmYz19kk
cancerletter.com
In 2009, Carl Ola Landgren noticed that nearly all of his multiple myeloma patients were responding to the state-of-the-art drugs he was giving them at the NCI clinical center in Building 10 in...
0
1
4
and here's a link to our previous medRxiv tweetorial if you want the key points: https://t.co/TUIM4YtlxT
Exciting preprint to share! With @dikokaz, @DrOlaLandgren , @FrancescoMaura4. Genomic profiling of high-risk smoldering multiple myeloma (HR-SMM) to contextualize the generally favorable results in trials of early tx intervention. https://t.co/wk4ontWWvn
#mmsm (1/n)
1
1
1
#mmsm @theMMRF With MRD as early endpoint for accelerated approval of new multiple myeloma drugs, patients' access to new therapies will be much quicker. Instead of waiting for 10-15 yrs, new drugs can be available in 3-5 yrs. Here is how it works:
vjhemonc.com
On 12th April 2024, a meeting of the US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) was held to assess the use of measurable residual disease (MRD) as a regulatory...
2
12
37
In a ‘Historical’ Moment FDA Committee Rules on a Faster Way to Approve Therapies for Myeloma Honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM @IMFmyeloma @theMMRF #mmsm @HealthTree @SylvesterCancer
news.med.miami.edu
An FDA advisory committee voted yes on how the agency evaluates new treatments for multiple myeloma, based on Sylvester research.
2
6
48
Former Artsakh State Minister, businessman, and philanthropist Ruben Vardanyan has been nominated for the 2024 Nobel Peace Prize for his charitable and humanitarian work. His candidacy was proposed by several influential individuals, including a Nobel Peace Prize laureate. The
12
109
419
Where have we or currently in for RRMM treatment #immunotherapy with Ken Shain. @DrOlaLandgren
1
0
4
How can we monitor MRD often given need of bone marrow biopsies? Blood based mass spec?
0
0
2
0
1
8
Happening Now!
Don’t miss ADVANCING PRECISION MEDICINE IN MYELOMA! NEW full day CME/CE Accredited Conference When: Sat April 6, 2024, 7:30am-3:30pm ET Where: Eden Roc, Miami Beach Register for FREE: https://t.co/Esxa6ayqib…
#mmsm @theMMRF @IMFmyeloma @HealthTree @SylvesterCancer
0
0
6